Correlation between esmolol usage in the acute phase of ischemic stroke and outcomes of patients undergoing intravenous thrombolysis

Figure 2 Kaplan-Meier 90-day survival curves. A: Kaplan-Meier 90-day survival curves of the esmolol-treated and esmolol-untreated subgroups among patients with atrial fibrillation who underwent intravenous thrombolysis (IT) for acute ischemic stroke (AIS). The survival rates were not significantly different between the esmolol-treated and esmolol-untreated subgroups (log-rank test; P = 0.807); B: Kaplan-Meier 90-day survival curves of the esmolol-treated and esmolol-untreated subgroups among patients with a history of hypertension who underwent IT for AIS. The survival rates were not significantly different between the esmolol-treated and esmolol-untreated subgroups (log-rank test; P = 0.23); C: Kaplan-Meier 90-day survival curves of the esmolol-treated and esmolol-untreated subgroups among patients without a history of hypertension who underwent IT for AIS. The survival rates were not significantly different between the esmolol-treated and esmolol-untreated subgroups (log-rank test; P = 0.13).